{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T13:13:05Z","timestamp":1784121185745,"version":"3.55.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T00:00:00Z","timestamp":1707177600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011928","name":"Schweizerische Arbeitsgemeinschaft f\u00fcr Klinische Krebsforschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011928","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.ejca.2024.113588","type":"journal-article","created":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T12:25:42Z","timestamp":1706876742000},"page":"113588","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65\/16)"],"prefix":"10.1016","volume":"201","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0602-8667","authenticated-orcid":false,"given":"Ilaria","family":"Colombo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6549-8124","authenticated-orcid":false,"given":"Kira-Lee","family":"Koster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Holer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9721-3314","authenticated-orcid":false,"given":"Simon","family":"Haefliger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6764-1844","authenticated-orcid":false,"given":"Manuela","family":"Rabaglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Bastian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schwitter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Eckhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2265-6559","authenticated-orcid":false,"given":"Stefanie","family":"Hayoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M.","family":"Mc Laughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Kloft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1706-6289","authenticated-orcid":false,"given":"Marian","family":"Klose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3641-6795","authenticated-orcid":false,"given":"Stefan","family":"Halbherr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Baumgartner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiana","family":"Sessa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasios","family":"Stathis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4993-8744","authenticated-orcid":false,"given":"Dagmar","family":"Hess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6602-6287","authenticated-orcid":false,"given":"Markus","family":"Joerger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejca.2024.113588_bib1","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/annonc\/mdh097","article-title":"Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer","volume":"15","author":"O'Brien","year":"2004","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2024.113588_bib2","first-page":"567","article-title":"Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation","volume":"2","author":"Rahman","year":"2007","journal-title":"Int J Nanomed"},{"issue":"10","key":"10.1016\/j.ejca.2024.113588_bib3","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1073\/pnas.85.10.3585","article-title":"Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol","volume":"85","author":"Olson","year":"1988","journal-title":"Proc Natl Acad Sci USA"},{"issue":"33","key":"10.1016\/j.ejca.2024.113588_bib4","doi-asserted-by":"crossref","first-page":"15851","DOI":"10.1016\/S0021-9258(18)47666-1","article-title":"The major metabolite of doxorubicin is a potent inhibitor of membrane-associated ion pumps. A correlative study of cardiac muscle with isolated membrane fractions","volume":"262","author":"Boucek","year":"1987","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.ejca.2024.113588_bib5","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/(SICI)1097-0142(19990701)86:1<72::AID-CNCR12>3.0.CO;2-1","article-title":"Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes","volume":"86","author":"Symon","year":"1999","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2024.113588_bib6","first-page":"987","article-title":"Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes","volume":"54","author":"Gabizon","year":"1994","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.ejca.2024.113588_bib7","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2165\/00003088-200342050-00002","article-title":"Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies","volume":"42","author":"Gabizon","year":"2003","journal-title":"Clin Pharm"},{"issue":"1-2","key":"10.1016\/j.ejca.2024.113588_bib8","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0168-3659(99)00248-5","article-title":"Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review","volume":"65","author":"Maeda","year":"2000","journal-title":"J Control Release"},{"issue":"1","key":"10.1016\/j.ejca.2024.113588_bib9","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/s41467-018-03705-y","article-title":"Progress and challenges towards targeted delivery of cancer therapeutics","volume":"9","author":"Rosenblum","year":"2018","journal-title":"Nat Commun"},{"issue":"14","key":"10.1016\/j.ejca.2024.113588_bib10","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan","volume":"19","author":"Gordon","year":"2001","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2024.113588_bib11","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.ejca.2005.12.011","article-title":"A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993)","volume":"42","author":"Coleman","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.113588_bib12","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1186\/1471-2407-11-373","article-title":"Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: results of an Austrian observational trial","volume":"11","author":"Fiegl","year":"2011","journal-title":"BMC Cancer"},{"issue":"19","key":"10.1016\/j.ejca.2024.113588_bib13","doi-asserted-by":"crossref","first-page":"3893","DOI":"10.1200\/JCO.2004.08.157","article-title":"Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer","volume":"22","author":"Keller","year":"2004","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2024.113588_bib14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2165\/00003088-198815010-00002","article-title":"Clinical pharmacokinetics of doxorubicin","volume":"15","author":"Speth","year":"1988","journal-title":"Clin Pharm"},{"issue":"5","key":"10.1016\/j.ejca.2024.113588_bib15","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/s00280-004-0900-4","article-title":"Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma","volume":"55","author":"Joerger","year":"2005","journal-title":"Cancer Chemother Pharm"},{"issue":"3","key":"10.1016\/j.ejca.2024.113588_bib16","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0009-9236(97)90162-4","article-title":"Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma","volume":"61","author":"Amantea","year":"1997","journal-title":"Clin Pharm Ther"},{"issue":"5","key":"10.1016\/j.ejca.2024.113588_bib17","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1365-2710.2009.01128.x","article-title":"Pharmacokinetics and its relation to toxicity of pegylated-liposomal doxorubicin in Chinese patients with breast tumours","volume":"35","author":"Xu","year":"2010","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.ejca.2024.113588_bib18","unstructured":"(EMA) EMA. Caelyx summary of product characteristics."},{"issue":"1","key":"10.1016\/j.ejca.2024.113588_bib19","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0005-2736(92)90136-A","article-title":"Role of liposome size and RES blockade in controlling biodistribution and tumor uptake of GM1-containing liposomes","volume":"1104","author":"Liu","year":"1992","journal-title":"Biochim Et Biophys Acta"},{"issue":"2","key":"10.1016\/j.ejca.2024.113588_bib20","doi-asserted-by":"crossref","first-page":"319","DOI":"10.7150\/thno.18078","article-title":"Improved Tumor Uptake by Optimizing Liposome Based RES Blockade Strategy","volume":"7","author":"Sun","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.ejca.2024.113588_bib21","unstructured":"(FDA) USFDA. Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. 2005."},{"key":"10.1016\/j.ejca.2024.113588_bib22","unstructured":"R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria, 2022.https:\/\/www.r-project.org\/."},{"issue":"1","key":"10.1016\/j.ejca.2024.113588_bib23","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10549-016-4033-3","article-title":"A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study","volume":"161","author":"Harbeck","year":"2017","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"10.1016\/j.ejca.2024.113588_bib24","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1038\/s41563-020-0755-z","article-title":"The dose threshold for nanoparticle tumour delivery","volume":"19","author":"Ouyang","year":"2020","journal-title":"Nat Mater"},{"issue":"5","key":"10.1016\/j.ejca.2024.113588_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/s41563-019-0566-2","article-title":"The entry of nanoparticles into solid tumours","volume":"19","author":"Sindhwani","year":"2020","journal-title":"Nat Mater"},{"issue":"9","key":"10.1016\/j.ejca.2024.113588_bib26","doi-asserted-by":"crossref","first-page":"14080","DOI":"10.1021\/acsnano.1c04510","article-title":"Specific endothelial cells govern nanoparticle entry into solid tumors","volume":"15","author":"Kingston","year":"2021","journal-title":"ACS Nano"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924000649?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924000649?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:43:40Z","timestamp":1760733820000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924000649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":26,"alternative-id":["S0959804924000649"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.113588","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65\/16)","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.113588","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"113588"}}